Filtered By:
Infectious Disease: COVID-19
Procedure: Liver Transplant

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 6 results found since Jan 2013.

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Unusual Symptoms of Coronavirus: What We Know So Far
While most people are familiar with the hallmark symptoms of COVID-19 by now—cough, fever, muscle aches, headaches and difficulty breathing—a new crop of medical conditions are emerging from the more than 4 million confirmed cases of the disease around the world. These include skin rashes, diarrhea, kidney abnormalities and potentially life-threatening blood clots. It’s not unusual for viruses to directly infect and affect different tissues and organs in the body, but it is a bit unusual for a primarily respiratory virus like SARS-CoV-2, which is responsible for COVID-19, to have such a wide-ranging reach...
Source: TIME: Health - May 19, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
Background As mortality from coronavirus disease 2019 (COVID-19) is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age-/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations. Methods We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including death, hospitalisation, intensive c...
Source: European Respiratory Review - November 2, 2022 Category: Respiratory Medicine Authors: Vardavas, C. I., Mathioudakis, A. G., Nikitara, K., Stamatelopoulos, K., Georgiopoulos, G., Phalkey, R., Leonardi-Bee, J., Fernandez, E., Carnicer-Pont, D., Vestbo, J., Semenza, J. C., Deogan, C., Suk, J. E., Kramarz, P., Lamb, F., Penttinen, P. Tags: Respiratory infections and tuberculosis Reviews Source Type: research

How AI Is Changing Medical Imaging to Improve Patient Care
That doctors can peer into the human body without making a single incision once seemed like a miraculous concept. But medical imaging in radiology has come a long way, and the latest artificial intelligence (AI)-driven techniques are going much further: exploiting the massive computing abilities of AI and machine learning to mine body scans for differences that even the human eye can miss. Imaging in medicine now involves sophisticated ways of analyzing every data point to distinguish disease from health and signal from noise. If the first few decades of radiology were about refining the resolution of the pictures taken of...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Alice Park and Video by Andrew D. Johnson Tags: Uncategorized Frontiers of Medicine 2022 healthscienceclimate Innovation sponsorshipblock Source Type: news

Excess mortality due to COVID-19 in Germany
SARS-CoV-2 is transmitted by droplets and likely aerosols. The median incubation period is about 5-6 days (range 1-14 days)1 and the median age at confirmed infection in Germany is 49 years. Typical symptoms include fever, cough, anosmia, ageusia, and pneumonia. The mortality rate of COVID-19 is higher among elderly and among ethnicities other than Caucasians. Furthermore, a markedly higher mortality rate has been observed for several comorbidities including obesity class II (BMI 35 •0-39•9 kg/m2) and III (BMI 40•0+ kg/m2), uncontrolled diabetes mellitus, malignancies in the previous year, severely reduced glomerular...
Source: Journal of Infection - September 17, 2020 Category: Infectious Diseases Authors: Andreas Stang, Fabian Standl, Bernd Kowall, Bastian Brune, Juliane B öttcher, Marcus Brinkmann, Ulf Dittmer, Karl-Heinz Jöckel Source Type: research